Figure 2
Figure 2. Binding of wild-type and engineered IgGs to classical human FcγRs. ELISA screening showing binding of titrated amounts of wild-type IgG1, IgG3, and engineered IgG3 variants to (A) hFcγRI, (B) hFcγRIIaH131, (C) hFcγRIIb, (D) hFcγRIIIa, and (E) hFcγRIIIb. The hinge-deleted antibodies IgG3ΔHinge and IgG3ΔHinge:R435H do not bind to any of the receptors; n = 3. All data are presented as mean ± SD.

Binding of wild-type and engineered IgGs to classical human FcγRs. ELISA screening showing binding of titrated amounts of wild-type IgG1, IgG3, and engineered IgG3 variants to (A) hFcγRI, (B) hFcγRIIaH131, (C) hFcγRIIb, (D) hFcγRIIIa, and (E) hFcγRIIIb. The hinge-deleted antibodies IgG3ΔHinge and IgG3ΔHinge:R435H do not bind to any of the receptors; n = 3. All data are presented as mean ± SD.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal